Thank you for your interest in viewing the FDA approves Radicava - What do we need to know? webinar! Please join us on May 10, 2017 at 6:00 PM - 6:00 PM EDT
The Food and Drug Administration announced today it has granted approval to MT Pharma America to begin marketing edaravone as a treatment for amyotrophic lateral sclerosis (ALS). The approval of edaravone marks the first new treatment to be approved for ALS in the United States since Rilutek® (Riluzole) was approved in 1995. This webinar will discuss what this important announcement means for people living with ALS today.